Sanofi: In line 2012 despite heavier Opex, disappointing guidance, mixed to negative R&D update

BUY, Fair Value Under Review

News published on February Thursday 7, 2013
Share on
Sanofi delivered this morning a press release that includes three main elements in our view: (i) full-year 2012 results that are good at the top line level thanks to outstanding Vaccines performance in Q4 and to a lesser extent for Genzyme as well. Lantus and new products did well but emerging markets were weak. Opex were heavier than expected and so operating margin was disappointing at 24.6% in Q4, 2pp lower than expected. Only a 19% tax rate in Q4 helped 2012 core EPS be in line with expectations; (ii) guidance for 2013 is shy, as we feared, with Core EPS anticipated between -5% and 0% which should translate in reported -7% to -2% considering currency fluctuations, far from the actual flat to 1% increase in consensus (BG: flat); (iii) update in R&D is mixed with second positive phase III for eliglustat but removal of Lantus/lixisenatide from phase III development planning.

Full report available to subscribers
Please contact

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities